



57-804

PHA 4140.18 (3475/2/US)  
PATENT

(fw)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Mark Obukowicz  
U.S. Application Serial No. 10/817,027  
Filing Date April 2, 2004  
Confirmation No. 2777  
For SELECTIVE COX-2 INHIBITION FROM PLANT EXTRACTS  
Examiner TBD

Art Unit 1654

July 7, 2004

TO THE COMMISSIONER FOR PATENTS,

SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

The references listed on the attached PTO/SB/08A, with the exception of reference 117, are of record in parent application Serial No. 10/022,862 and, therefore, in accordance with MPEP 609, \* are not being provided at this time. Reference 117 is attached.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicant believes that it is being filed before the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. 1.97(c) is required. If Applicant is mistaken, and the mailing date of the first Office action on the merits precedes the filing of this Information Disclosure Statement, Applicant authorizes the Commissioner to charge the fee due under 37 C.F.R. 1.17(p) to Deposit Account No. 19-1345.

Respectfully submitted,

Timothy B. McBride, Reg. No. 47,781  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

TBM/sxm

\* Enclosures

Mail Stop Amendment

Express Mail Label No. EV 432653910 US

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet	1	of	Attorney Docket No.	3475/2/US (PHA 4140.18)
-------	---	----	---------------------	-------------------------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1	4,313,958		LaHann	02-02-1982
	2	4,324,785		Stevens	04-13-1982
	3	4,613,591	B1	Aburada et al.	09-23-1986
	4	4,767,626	A	Cheng	08-30-1998
	5	5,380,738	B1	Norman et al.	01-10-1995
	6	5,344,991	B1	Reitz et al.	09-06-1994
	7	5,393,790	B1	Reitz et al.	02-28-1995
	8	5,466,823	B1	Talley et al.	11-14-1995
	9	5,521,207	B1	Graneto	05-28-1996
	10	5,633,272	B1	Talley et al.	05-27-1997
	11	5,753,688	B1	Talley et al.	05-19-1998
	12	5,760,068	B1	Talley et al.	06-02-1998
	13	5,762,963	A	Byas-Smith	06-09-1998
	14	5,811,425	B1	Woods et al.	09-22-1998
	15	5,824,312	A	Unger et al.	10-20-1999

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/817,027
Filing Date	04/02/04
Confirmation Number	2777
First Named Inventor	M. Obukowicz
Group Art Unit	1654

Sheet	2	of	9	Attorney Docket No.	3475/2/US (PHA 4140.18)
-------	---	----	---	---------------------	-------------------------

	16	5,932,598	B1	Talley et al.	08-03-1999
	17	6,197,823	B1	Barr et al.	03-06-2001
	18	6,217,875	B1	Okada et al.	04-17-2001
	19	6,277,398	B1	Caruso	08-21-2001
	20	6,310,091	B1	DeLucca, II et al.	10-30-2001
	21	6,348,501	B1	Holt et al.	02-19-2002

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
22	EP	248215	B1	Popp et al.	12-09-1987		
23	GB	2 168 975	A	Janusz	07-02-1986		
24	GB	2335599	A	Xia et al.	09-29-1999		
25	JP	10 298098	A	Oryza Oil & Fat Chem (US)	04-17-2001	A	
26	JP	4208222		Tsumura & co.	07-29-1992	X	
27	JP	4005237	A	Nonogawa Shoji:kk (abstract)	01-09-1992		
28	JP	58 024523	A	Terumo kk	02-14-1983	A	
29	JP	82 045412	A	Norin Suisansyo Chugoku Nogyo Shikenjo	09-24-1996	A	
30	JP	90 067360	A	Terumo Corp.	03-11-1997	A	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/817,027
Filing Date	04/02/04
Confirmation Number	2777
First Named Inventor	M. Obukowicz
Group Art Unit	1654

Sheet	3	of	9	Attorney Docket No.	3475/2/US (PHA 4140.18)
-------	---	----	---	---------------------	-------------------------

	31	JP	00 239169	A	Lotte Co. Ltd.	09-04-2000	A
	32	JP	2000236835		Seika et al. (abstract)	09-05-2000	
	33	WO	93/13055	A	Glaxo Wellcome Inc.	07-08-1993	
	34	WO	94/12165	A	Wellcome et al.	06-09-1994	
	35	WO	94/14780	A	Wellcome et al.	07-07-1994	
	36	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	37	WO	95/11231	A	Bergmanis et al.	04-27-1995	
	38	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	39	WO	98/17292	A1	Sloth-Weidner	04-30-1998	
	40	WO	99/62532	A	Baylor College of Medicine	12-09-1999	
	41	WO	00/33824	A2	Nair et al.	06-15-2000	
	42	WO	00/40258	A1	Butters et al.	07-13-2000	
	43	WO	00/56348	A1	Corley et al.	09-28-2000	
	44	WO	00/72861	A	Armadillo Pharmaceuticals	12-07-2000	
	45	WO	00/74696	A1	Oxford Natural Products PLC	12-14-2000	

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	46	ABAD et al., "Anti-inflammatory Activity of Hydroxyachillin, a Sesquiterpene Lactone from <i>Tanacetum microphyllum</i> ", <i>Planta Med.</i> , 1994, pp. 228-231, Vol. 60.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	4	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

	47	ABAD et al., "The Activity of Flavonoids Extracted from <i>Tanacetum microphyllum</i> DC. (Compositae) on Soybean Lipoxygenase and Prostaglandin Synthetase, Gen. Pharmacolm 1995, pp. 815-819, Vol. 26, No. 4.
	48	ALANKO et al., "Modulation of arachidonic acid metabolism by phenols: Relation to their structure and anti-oxidant/pro-oxidant properties." Free Radical Biology and Medicine 1999, pp. 193-201, Vol. 26.
	49	AUERBACH et al., "A Spectrophotometric Microtiter-Based Assay for the Detection of Hydroperoxy Derivatives of Linoleic Acid." Anal. Biochem, 1992, pp. 375-380, Vol. 201.
	50	BATRISTINI et al., COX-1 and COX-2: Toward the development of More selective NSAIDs, <i>DN&amp;P</i> , 1994, pp. 50-512, Vol. 7, No. 8.
	51	BINGOL et al., A Review of Terrestrial Plants and Marine Organisms Having Antiinflammatory Activity. International Journal of Pharmacognosy, 1995, pp. 81-97, Vol. 33, No. 2.
	52	CARTER, et al., 5-Lipoxygenase inhibitory activity of Zileuton, <i>J. Pharmacol. &amp; Exp. Ther</i> , 1991, pp. 929-937, Vol. 256, Vol. 3.
	53	CHANG et al., "The Influence of Chinese Traditional Medicine on the Production and Activity of Interleukin 1", Chinese J. Microbiol. Immunol., 1993, pp. 15-24, Vol. 26.
	54	CHOU et al., "The inhibitory effect of common traditional anti-rheumatic herb formulas on prostaglandin E and interleukin 2 in vitro: A comparative study with <i>Tripterygium wilfordii</i> ", <i>J. Ethnopharmacol.</i> , 1998, pp. 167-171, Vol. 62, No. 2.
	55	COHEN et al., "Cytokine Function" <i>Am. J. Clin. Pathol.</i> , 1996, pp. 589-598, Vol. 105., No. 5.
	56	DANZ et al., "Identification and Isolation of the Cyclooxygenase-2 Inhibitory Principle in <i>Isatis tinctoria</i> , <i>Planta Med.</i> 67, pp. 411-416, Vol. 67.
	57	DEWITT et al., "The Differential Susceptibility of Prostaglandin Endoperoxide H Synthases-1 and -2 to Nonsteroidal Anti-Inflammatory Drugs: Aspirin Derivatives as Selective Inhibitors." <i>Med Chem Res</i> , 1995, pp. 325-343, Vol. 5.
	58	DUKE, J., "Clippings from my COX Box." <i>Journal of Medicinal Food</i> , 1998/1999, pp. 293-298, Vol. 1, No. 4.

Examiner Signature		Date Considered	.
-----------------------	--	--------------------	---

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	5	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

	59	DUNSTAN et al., "Evaluation of some Samoan and Peruvian medicinal plants by prostaglandin biosynthesis and rat ear oedema assays", J. Ethnopharmacol, 1997, pp. 35-56, Vol. 57, No. 1.
	60	ELIAS et al., "Synergistic Stimulation of Fibroblast Prostaglandin Production by Recombinant Interleukin 1 and Tumor Necrosis Factor", J. Immunol., 1987, pp. 3812-3816, Vol. 138.
	61	EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation", Science, 1989, pp. 1617-1620, Vol. 246.
	62	GIERSET et al., "A single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors." The Journal of Biological Chemistry, 1996, pp. 15810-15814, Vol. 271, No. 26.
	63	HAQQI et al., "Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea", Proc. Natl. Acad. Sci. USA, 1999, pp. 4524-4529, Vol. 96.
	64	HENDERSON et al., "Therapeutic potential of cytokine manipulation", TIPS, 1992, pp. 145-152, Vol. 13.
	65	JAGER et al., "Screening of Zulu medicinal plants for prostaglandin synthesis inhibitors", J. Ethnopharmacol, 1996, pp. 95-100, Vol. 52, No. 2.
	66	JANG et al., "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes." Science 1997, pp. 218-220, Vol. 275.
	67	JUERGENS, U.R., et. al., "The Anti-Inflammatory Activity of L-Menthol Compared to Mint Oil in Human Monocytes In Vitro: A Novel Perspective For Its Therapeutic Use in Inflammatory Diseases", Eur. J. Med. Res., 1998, pp. 539-545.
	68	JUERGENS, U.R., et. al., "Inhibition of Cytokine Production And Arachidonic Acid Metabolism By Eucalyptol (1,8-Cineole) In Human Blood Monocytes In Vitro", Eur. J. Med. Res., 1998, pp. 508-510
	69	KALGUTKAR et al., Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2, Science, 1998, pp. 1268-1270, Vol. 280.
	70	KALGUTKAR, et al., Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective Cox-2 Inhibitors, PNAS, 2000, pp. 925-930, Vol. 97, No. 2.

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	6	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

71	KARTTUMEN et al., "Measurement of ligand-induced activation in single viable T cells using the <i>lacZ</i> reporter gene", Proc. Nat'l. Acad. Sci, 1991, pp. 3972-3976, Vol. 88.		
72	KASE, et al., Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels, <i>Biol. Pharm. Bull.</i> , 1998, pp. 1277-1281, Vol. 21, No. 12.		
73	KIM et al., "Effects of naturally- occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea pigs", <i>Prostaglandins Leukot. Essent. Fatty Acids</i> , 1998 58(1); pp. 17-24.		
74	KOIZUMI et al., "Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat," <i>Cellular Immunology</i> , 1986, pp. 469-475, Vol. 103.		
75	LAVALLE, James B. (2001) <i>The COX-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer</i> . Healing Arts Press. (Table of Contents only).		
76	LEE et al. "a-Viniferin: A Prostaglandin H2 Synthase Inhibitor from Root of <i>Carex humilis</i> ", <i>Planta Med.</i> , 1998, pp. 195-290, Vol. 64.		
77	LENARDO et al., "NF- $\kappa$ B: A Pleiotrophic Mediator of Inducible and Tissue-Specific Gene Control", <i>Cell</i> , 1989, pp. 227-229, Vol. 58.		
78	LINDSEY et al., "Screening of plants used by Southern African traditional healers in the treatment of dysmenorrhoea for prostaglandin-synthesis inhibitors and uterine relaxing activity." <i>Journal of Ethnopharmacology</i> 1999, pp. 9-14, Vol. 64.		
79	LIU et al., "Inhibitory Effects of <i>Angelica pubescens f. biserrata</i> on 5-Lipoxygenase and Cyclooxygenase", <i>Planta Med.</i> , 1998, pp. 525-529, Vo. 64.		
80	MCADAM et al., "Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of Cox-2." <i>Proc. Nat. Acad. Sci. USA</i> , 1999, pp. 272-277, Vol. 96.		
81	MALOFF et al., "Development of an RIA-based primary screen for IL-1 antagonists" <i>Clin. Chim. Acta.</i> , 1988, pp. 73-78, Vol. 180.		
82	MARNETT et al., Arachidonic Acid Oxygenation by COX-1 and COX-2, <i>The Journal of Biological Chemistry</i> , 1999, pp. 22903-22906, Vol. 274, No. 33.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	7	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

83	MICHALUART et al, "Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Activity and Expression of Cyclooxygenase-2 in Human Oral Epithelial Cells and in a Rat Model of Inflammation", Cancer Res.1999, Vol. 59, pp. 2347-2352.
84	MIN, K.R. et al. "(-) -Epiafzelechin: Cyclooxygenase-1 Inhibitor and Anti-Inflammatory Agency from Aerial Parts of <i>Celastrus orbiculatus</i> ", Planta Med., 1999, pp. 460-462, Vol. 65.
85	MITCHELL et al., "Cyclooxygenase-2: Regulation and Relevance in Inflammation." Biochemical Pharmacology, 1995, pp. 1535-1542, Vol. 50, No. 10.
86	MOON et al., "A new class of COX-2 inhibitor, rutaecarpine from <i>Evodia rutaecarpa</i> ", Inflamm. Res., 1999, Vol. 48, pp. 621-625
87	NEWMARK et al. (2000) Beyond Aspirin: Nature's Answer to Arthritis, Cancer, and Alzheimer's Disease. Hohm Press, Prescott, AZ. (Table of Contents only).
88	NOREEN et al., "Flavan-3-ols isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis", 1998, pp. 520-524, Vol. 64.
89	NOREEN et al., "Development of a Radiochemical Cyclooxygenase-1 and -2 in Vitro Assay for Identification of Natural Products as Inhibitors of Prostaglandin Biosynthesis", J. Nat. Prod., 1998, Vol. 61, No. 1.
90	NOWLIN et al., "A Novel Cyclic Pentapeptide Inhibits $\alpha$ 4 $\beta$ 1 and $\alpha$ 5 $\beta$ 1 Integrin-mediated cell Adhesion." J. Biol. Chem, 1993, pp. 20352-20359, Vol. 268.
91	O'NEILL et al., "Overexpression of Human Prostaglandin G/H Synthase-1 and -2 by Recombinant Vaccinia Virus: Inhibition by Nonsteroidal Anti-Inflammatory Drugs and Biosynthesis of 15-Hydroxyeicosatetraenoic Acid." Mole. Pharmacol, 1994, pp. 245-254, Vol. 45.
92	PENNISI, E., Building a Better Aspirin, Science, 1998, pp. 1191-1192, Vol. 280.
93	REDDY et al., "Studies on Anti-Inflammatory Activity of Spice Principles and Dietary n-3 Polyunsaturated Fatty Acids on Carrageenan-Induced Inflammation in Rats", Ann. Nutr. Metab., 1994, pp. 349-358.
94	REDDY et al., "Selective Inhibition of Cyclooxygenase-2 by C-Phycocyanin, a Biliprotein from <i>Spirulina platensis</i> ", Biochem. Biophys. Res. Commun, 2000, Vol. 277, No. 3.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	8	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

	95	RESCH et al., 5-Lipoxygenase and Cyclooxygenase-1 Inhibitory Active Compounds from <i>Atractylodes Lancea</i> , <i>J. Nat. Prod.</i> , 1998, pp. 347-350, Vol. 61.
	96	RESCH et al., "Further Phenols and Polyacetylenes from the Rhizomes of <i>Atractylodes lancea</i> and their Anti-Inflammatory Activity", <i>Planta Med.</i> , 2001, pp. 437-442. Vol. 67.
	97	RINGBOM et al., Ursolic Acid from <i>Plantago major</i> , a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis, <i>J. Nat. Prod.</i> , 1998, pp. 1212-1215, Vol. 61, No. 10.
	98	RINGBOM et al., "COX-2 Inhibitory Effects of Naturally Occurring and Modified Fatty Acids", <i>J. Nat. Prod.</i> , 2001, pp., 745-749, Vol. 64, No. 6.
	99	RUBIN, et al., Pharmacokinetics, Safety, and Ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase, <i>Agents Actions Suppl.</i> , 1991, pp. 103-116, Vol. 35. (abstract only)
	100	SEGURA et al., "Anti-Inflammatory Activity of Dichloromethane Extract of <i>Heterotheca inuloides</i> in Vivo and in Vitro", <i>Planta Med.</i> , 2000, pp. 553-555, Vol. 66.
	101	STOLTENBORG et al., "A fluorescent cellular adhesion assay using insect cell produced human VCAM1", <i>J. Immunological Methods</i> , 1994, pp. 59-68, Vol. 175.
	102	SUBBARAMAIAH et al., Resveratrol Inhibits the Expression of Cyclooxygenase-2 in Human Mammary and Oral Epithelial Cells, <i>Pharmaceutical Biology</i> , 1998, pp. 35-43, Vol. 36.
	103	SUBBARAMAIAH et al., "Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells", 1998, <i>J. Biol. Chem.</i> 273(34):21875-21882.
	104	SUBBARAMAIAH et al., "Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells", <i>Ann. N.Y. Acad. Sci.</i> , 1999, Vol. 889, pp. 214-223.
	105	SUBBARAMAIAH et al., "Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells", <i>Cancer Res.</i> 2000, Vol. 60, pp. 2399-2404.
	106	TAYLOR et al., "COX-1 inhibitory activity in extracts from <i>Eucomis L'Herit. species</i> ", <i>J. Ethnopharmacol.</i> , 2001, pp. 257-265, Vol. 76, Nos. 2-3.
	107	TUNON et al., "Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis", <i>J. Ethnopharmacol</i> 48, 1995, pp. 61-76.

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number				10/817,027
Filing Date				04/02/04
Confirmation Number				2777
First Named Inventor				M. Obukowicz
Group Art Unit				1654
Sheet	9	of	9	Attorney Docket No.
				3475/2/US (PHA 4140.18)

	108	TYLER, Varro E., "Phytomedicines: Back to the Future.", J. Nat. Prod., 1999, pp. 1589-1592.	
	109	YOU et al., "Inhibition of Cyclooxygenase/Lipoxygenase from Human Platelets by Polyhydroxylated/Methoxylated Flavonoids Isolated from Medicinal Plants", Arch. Pharm. Res. 1999, pp. 18-24, Vol. 22, No. 1.	
	110	WANG et al., "Antioxidant and Antiinflammatory Activities of Anthocyanins and Their Aglycon, Cyanidin, from Tart Cherries", J. Nat. Prod., 1999, pp. 294- 296, Vol. 62, No. 2.	
	111	WELKER et al., "Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells", International Arch of Allergy and Immunology, 1996, pp. 110-115, Vol. 109.	
	112	WHITEHOUSE et al., "Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?" Inflammopharmacology, 1999, pp. 89-105, Vol. 7, No. 2.	
	113	WILLIAMS et al. "The flavonoids of <i>Tanacetum parthenium</i> and <i>T. vulgare</i> and their anti-inflammatory properties." Phytochemistry 1999, pp. 417-423, Vol. 51, No. 3.	
	114	ZENG, X., et al, "Studies on anti-inflammatory and analgesic effects of <i>Dracaena cochinchinensis</i> ", Zhongguo Zhongyao Zazhi, 1999, 24(3), pp. 171-173.	A
	115	ZHANG et. al., "Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells", Carcinogenesis, 1999, Vol. 20, No. 3.	
	116	ZSCHOCKE et al., "5-Lipoxygenase and Cyclooxygenase Inhibitory Active Constituents from Qianghuo ( <i>Notopterygium incisum</i> )", Planta Med., 1997, pp. 203-206, Vol. 63.	
	117	Nexrtine brochure for Remedief, "Triple Action Pain Management with Natural Cox-2 Inhibitor." Undated	
	118	Hawley's Condensed Chemical Dictionary, 13th Edition, Revised by Lewis, 1997, page 736.	
	119	J. Heterocyclic Chem. 1982, pp. 193-200, Vol. 19, No. 1.	
	120	International Search Report for PCT/US01/48912 dated 10/22/03; 14 pgs.	
	121	International Search Report for PCT/US01/48650 dated 10/22/03; 16 pgs.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.